Anti-Mullerian Hormone and Fertility Treatment Decisions in Polycystic Ovary Syndrome: A Literature Review-Reference-Cited by-同舟云学术

Anti-Mullerian Hormone and Fertility Treatment Decisions in Polycystic Ovary Syndrome: A Literature Review

Published:2024-01 Issue:1 Volume:17 Page:16-24
ISSN:0974-1208
Container-title:Journal of Human Reproductive Sciences
language:en
Short-container-title:

Author:

Shah Duru¹,Jirge Padma Rekha²

Affiliation:

1. Gynaecworld, The Centre for Women’s Health and Fertility, Mumbai, Maharashtra, India

2. Sushrut Assisted Conception Clinic, Shreyas Hospital, Kolhapur, Maharashtra, India

Abstract

ABSTRACT Anti-Mullerian hormone is a robust marker of ovarian reserve and ovarian response in in vitro fertilisation (IVF). However, its role extends beyond improving the safety of IVF by aiding in choosing appropriate protocols and dosing. This review looks at the value of pre-treatment anti-Mullerian hormone (AMH) value in choosing the appropriate modality of treatment and its predictive ability for the outcomes of such treatment. It briefly addresses the factors that may modulate AMH levels and make clinical decision-making challenging.

Publisher

Medknow

Reference94 articles.

1. Follicular dynamics in the polycystic ovary syndrome;Franks;Mol Cell Endocrinol,2000

2. Polycystic ovary syndrome;Norman;Lancet,2007

3. Relationship between serum müllerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women;Cook;Fertil Steril,2002

4. Anti-Müllerian hormone expression pattern in the human ovary:Potential implications for initial and cyclic follicle recruitment;Weenen;Mol Hum Reprod,2004

5. Mullerian inhibiting substance is an ovarian growth factor of emerging clinical significance;Seifer;Fertil Steril,2007